Cargando…

Tepotinib suppresses proliferation, invasion, migration, and promotes apoptosis of melanoma cells via inhibiting MET and PI3K/AKT signaling pathways

Malignant melanoma seriously threatens public health and lowers the quality of life of the affected subjects. The present study was designed to explore the effects of tepotinib, a selective tyrosine kinase inhibitor of MET proto-oncogene, receptor tyrosine kinase (MET), on the progression of melanom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jing, Guifang, Yu, Fang, Xue, Huandong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019857/ https://www.ncbi.nlm.nih.gov/pubmed/35497936 http://dx.doi.org/10.3892/ol.2022.13290

Ejemplares similares

Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding
por: Grädler, Ulrich, et al.
Publicado: (2023)

Breviscapine regulates the proliferation, migration, invasion, and apoptosis of colorectal cancer cells via the PI3K/AKT pathway
por: Niu, Pengfei, et al.
Publicado: (2023)

CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway
por: Hou, Teng, et al.
Publicado: (2017)

Osthole induces apoptosis and suppresses proliferation via the PI3K/Akt pathway in intrahepatic cholangiocarcinoma
por: Zhu, Xingyang, et al.
Publicado: (2017)

The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
por: Albers, Joachim, et al.
Publicado: (2023)

SCARA5 suppresses the proliferation and migration, and promotes the apoptosis of human retinoblastoma cells by inhibiting the PI3K/AKT pathway
por: Wang, Jinwei, et al.
Publicado: (2021)

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
por: Shitara, Kohei, et al.
Publicado: (2020)

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
por: Pudelko, Linda, et al.
Publicado: (2020)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Effects of miR‐145‐5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways
por: Liu, Sha, et al.
Publicado: (2017)

Correction: CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway
por: Hou, Teng, et al.
Publicado: (2019)

Knockdown of UBE2T Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion by Suppressing the PI3K/Akt Signaling Pathway
por: Wang, Yu, et al.
Publicado: (2016)

Effects of Cynaroside on Cell Proliferation, Apoptosis, Migration and Invasion though the MET/AKT/mTOR Axis in Gastric Cancer
por: Ji, Juanli, et al.
Publicado: (2021)

PGM1 suppresses colorectal cancer cell migration and invasion by regulating the PI3K/AKT pathway
por: Zheng, Zhewen, et al.
Publicado: (2022)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT–Mediated EMT
por: Xu, En, et al.
Publicado: (2020)

TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway
por: Lu, Qiang, et al.
Publicado: (2016)

A case of successful desensitization treatment with tepotinib after tepotinib-induced rash
por: Tamura, Tomoki, et al.
Publicado: (2023)

MicroRNA-126-3p suppresses HeLa cell proliferation, migration and invasion, and increases apoptosis via the PI3K/PDK1/AKT pathway
por: Ichikawa, Ryoko, et al.
Publicado: (2020)

Melatonin inhibits proliferation, migration, and invasion by inducing ROS-mediated apoptosis via suppression of the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells
por: Chen, Kunlun, et al.
Publicado: (2021)

EEF1D Promotes Glioma Proliferation, Migration, and Invasion through EMT and PI3K/Akt Pathway
por: Xie, Cheng, et al.
Publicado: (2020)

Combretastatin A4 Regulates Proliferation, Migration, Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt Signaling Pathway
por: Liang, Weixin, et al.
Publicado: (2016)

Mifepristone inhibits proliferation, migration and invasion of HUUA cells and promotes its apoptosis by regulation of FAK and PI3K/AKT signaling pathway
por: Sang, Lin, et al.
Publicado: (2018)

Corrigendum: GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT–Mediated EMT
por: Xu, En, et al.
Publicado: (2022)

Saquayamycin B(1) Suppresses Proliferation, Invasion, and Migration by Inhibiting PI3K/AKT Signaling Pathway in Human Colorectal Cancer Cells
por: Li, Jianjiang, et al.
Publicado: (2022)

Signal peptidase 21 suppresses cell proliferation, migration, and invasion via the PTEN-PI3K/Akt signaling pathway in lung adenocarcinoma
por: Zhang, Na, et al.
Publicado: (2022)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

Knockdown of Ski decreases osteosarcoma cell proliferation and migration by suppressing the PI3K/Akt signaling pathway
por: Zhao, Xin, et al.
Publicado: (2019)

Proliferation, migration and invasion of triple negative breast cancer cells are suppressed by berbamine via the PI3K/Akt/MDM2/p53 and PI3K/Akt/mTOR signaling pathways
por: Liu, Lili, et al.
Publicado: (2021)

Pentamidine inhibits proliferation, migration and invasion in endometrial cancer via the PI3K/AKT signaling pathway
por: Lin, Lin, et al.
Publicado: (2022)

Sanguinarine inhibits melanoma invasion and migration by targeting the FAK/PI3K/AKT/mTOR signalling pathway
por: Qi, Xiaoyi, et al.
Publicado: (2023)

AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway
por: Zheng, Jianping, et al.
Publicado: (2022)

Lyn Kinase Promotes the Proliferation of Malignant Melanoma Cells through Inhibition of Apoptosis and Autophagy via the PI3K/Akt Signaling Pathway
por: Zhang, Qianqian, et al.
Publicado: (2019)

Knockdown of ARHGAP30 inhibits ovarian cancer cell proliferation, migration, and invasiveness by suppressing the PI3K/AKT/mTOR signaling pathway
por: Chu, Xiaoyan, et al.
Publicado: (2023)

Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study
por: Xiong, Wenyuan, et al.
Publicado: (2022)

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
por: Decaens, Thomas, et al.
Publicado: (2021)

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study
por: Wu, Zhuo-Xun, et al.
Publicado: (2022)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations
por: Paik, Paul K., et al.
Publicado: (2022)

REG3A overexpression suppresses gastric cancer cell invasion, proliferation and promotes apoptosis through PI3K/Akt signaling pathway
por: Qiu, Yan-Song, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ma335ao3itkf2bs4pcisd3krqd